Raleigh Capital Management Inc. Sells 11,248 Shares of Labcorp Holdings Inc. $LH

Raleigh Capital Management Inc. cut its holdings in Labcorp Holdings Inc. (NYSE:LH) by 98.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 145 shares of the medical research company’s stock after selling 11,248 shares during the period. Raleigh Capital Management Inc.’s holdings in Labcorp were worth $36,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Caldwell Trust Co bought a new position in Labcorp during the 2nd quarter valued at about $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Labcorp during the 4th quarter valued at about $26,000. JPL Wealth Management LLC bought a new position in Labcorp during the 3rd quarter valued at about $28,000. Motco bought a new position in Labcorp during the 3rd quarter valued at about $32,000. Finally, Beacon Financial Strategies CORP bought a new position in Labcorp during the 4th quarter valued at about $33,000. 95.94% of the stock is currently owned by institutional investors.

Insider Activity at Labcorp

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $290.42, for a total value of $25,266.54. Following the completion of the sale, the executive vice president directly owned 2,782 shares of the company’s stock, valued at $807,948.44. The trade was a 3.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the sale, the executive vice president directly owned 2,579 shares of the company’s stock, valued at $734,782.89. The trade was a 17.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,113 shares of company stock valued at $4,547,450 in the last quarter. Corporate insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Wall Street Zen downgraded shares of Labcorp from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Morgan Stanley reiterated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Finally, Robert W. Baird upped their price target on shares of Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $307.70.

Labcorp Price Performance

Labcorp stock opened at $269.18 on Wednesday. The stock has a market cap of $22.18 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 1.87 and a beta of 1.02. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. Labcorp Holdings Inc. has a 1 year low of $209.38 and a 1 year high of $293.72. The firm has a 50-day moving average of $274.38 and a two-hundred day moving average of $268.85.

Labcorp (NYSE:LH) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.12. The company had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Friday, February 27th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend was Friday, February 27th. Labcorp’s payout ratio is 27.53%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.